mRNA Shot Offers Efficacy for Influenza-Like Illness
A new investigational mRNA-based vaccine, mRNA-1010, has demonstrated superior efficacy compared to a standard-dose seasonal influenza vaccine in preventing influenza-like illness in adults aged 50 and older. The phase 3 trial showed a relative vaccine efficacy of 26.6% for mRNA-1010, with a comparable safety profile. However, adverse events were reported more frequently with mRNA-1010, including injection-site pain and fatigue.
- ▪The mRNA-1010 vaccine showed a relative vaccine efficacy of 26.6% compared to the standard-dose vaccine.
- ▪Adverse events were more common with mRNA-1010, particularly injection-site pain and fatigue.
- ▪The study involved 40,703 participants aged 50 years or older during the 2024-2025 influenza season.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:A single dose of an investigational mRNA-based vaccine called mRNA-1010 vaccine showed superior efficacy to a licensed standard-dose inactivated seasonal influenza vaccine in preventing influenza-like illness among adults aged 50 years or older, with a comparable safety profile. METHODOLOGY:This phase 3 randomized trial, conducted during the 2024-2025 Northern Hemisphere influenza season, investigated the efficacy of the mRNA-1010 vaccine — which encodes hemagglutinin glycoproteins from World Health Organization-recommended influenza strains — vs licensed standard‑dose seasonal influenza vaccines for preventing laboratory‑confirmed influenza‑like illness in adults aged 50 years or older.Overall, 40,703 vaccine recipients were assigned to receive a single intramuscular dose of…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
